î
îŒ
î
Roivant Sciences Ltd
ROIV22.410USD
+0.620+2.85%
çµå€Â 12/19, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
15.46Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Roivant Sciences Ltd äŒæ¥å
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãROIV
äŒç€ŸåRoivant Sciences Ltd
äžå Žæ¥Dec 03, 2020
æé«çµå¶è²¬ä»»è
ãCEOãVenker (Eric)
åŸæ¥å¡æ°750
蚌åžçš®é¡Ordinary Share
決ç®ææ«Dec 03
æ¬ç€Ÿæåšå°7Th Floor, 50 Broadway
éœåžLONDON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited Kingdom
éµäŸ¿çªå·SW1H 0DB
é»è©±çªå·4412955950
ãŠã§ããµã€ãhttp://roivant.com/
äŒæ¥ã³ãŒãROIV
äžå Žæ¥Dec 03, 2020
æé«çµå¶è²¬ä»»è
ãCEOãVenker (Eric)
Roivant Sciences Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.34M
-0.52%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
186.45K
-0.66%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.14K
+0.69%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
+4.20%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
40.50K
+2.68%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.34M
-0.52%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
186.45K
-0.66%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
åçå èš³
FY2025Q1
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
VTAMA
55.13M
0.00%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
55.13M
0.00%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
VTAMA
55.13M
0.00%
æ ªäž»
æŽæ°æå»: Sun, Nov 16
æŽæ°æå»: Sun, Nov 16
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
Morgan Stanley Investment Management Inc. (US)
5.85%
SB Investment Advisers (UK) Limited
5.80%
ä»ã®
58.07%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
Morgan Stanley Investment Management Inc. (US)
5.85%
SB Investment Advisers (UK) Limited
5.80%
ä»ã®
58.07%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
27.37%
Investment Advisor/Hedge Fund
19.48%
Hedge Fund
15.22%
Corporation
14.79%
Individual Investor
10.61%
Private Equity
9.04%
Research Firm
1.64%
Pension Fund
0.51%
Venture Capital
0.46%
ä»ã®
0.88%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Dexcel Pharma Technologies, Ltd.
102.85M
15.06%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
55.50M
8.13%
+3.83M
+7.41%
Jun 30, 2025
Ramaswamy (Vivek)
48.92M
7.16%
-1.78M
-3.50%
Sep 05, 2025
Morgan Stanley Investment Management Inc. (US)
33.37M
4.89%
+2.37M
+7.64%
Jun 30, 2025
SB Investment Advisers (UK) Limited
59.95M
8.78%
-1.90M
-3.07%
Jun 30, 2025
The Vanguard Group, Inc.
39.25M
5.75%
-1.44M
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
35.53M
5.2%
-1.48M
-4.00%
Jun 30, 2025
QVT Financial LP
29.38M
4.3%
-36.41M
-55.34%
Jun 30, 2025
Viking Global Investors LP
34.24M
5.01%
-11.78M
-25.59%
Jun 30, 2025
Rubric Capital Management LP
20.37M
2.98%
+2.60M
+14.65%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
詳现ãèŠã
Invesco S&P MidCap 400 Pure Growth ETF
æ¯ç3.56%
Adaptiv Select ETF
æ¯ç2.91%
Virtus LifeSci Biotech Products ETF
æ¯ç2.79%
State Street SPDR S&P Biotech ETF
æ¯ç2.67%
WisdomTree US Value Fund
æ¯ç2.3%
ProShares Ultra Nasdaq Biotechnology
æ¯ç1.73%
Goldman Sachs Future Health Care Equity ETF
æ¯ç1.73%
Direxion Daily S&P Biotech Bull 3X Shares
æ¯ç1.41%
Invesco Nasdaq Biotechnology ETF
æ¯ç1.33%
WisdomTree BioRevolution Fund
æ¯ç1.3%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Roivant Sciences Ltdã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îRoivant Sciences Ltdã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Dexcel Pharma Technologies, Ltd.ã¯102.85Mæ ªãä¿æããŠãããããã¯å šäœã®15.06%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯55.50Mæ ªãä¿æããŠãããããã¯å šäœã®8.13%ã«çžåœããŸãã
Ramaswamy (Vivek)ã¯48.92Mæ ªãä¿æããŠãããããã¯å šäœã®7.16%ã«çžåœããŸãã
Morgan Stanley Investment Management Inc. (US)ã¯33.37Mæ ªãä¿æããŠãããããã¯å šäœã®4.89%ã«çžåœããŸãã
SB Investment Advisers (UK) Limitedã¯59.95Mæ ªãä¿æããŠãããããã¯å šäœã®8.78%ã«çžåœããŸãã
Dexcel Pharma Technologies, Ltd.ã¯102.85Mæ ªãä¿æããŠãããããã¯å šäœã®15.06%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯55.50Mæ ªãä¿æããŠãããããã¯å šäœã®8.13%ã«çžåœããŸãã
Ramaswamy (Vivek)ã¯48.92Mæ ªãä¿æããŠãããããã¯å šäœã®7.16%ã«çžåœããŸãã
Morgan Stanley Investment Management Inc. (US)ã¯33.37Mæ ªãä¿æããŠãããããã¯å šäœã®4.89%ã«çžåœããŸãã
SB Investment Advisers (UK) Limitedã¯59.95Mæ ªãä¿æããŠãããããã¯å šäœã®8.78%ã«çžåœããŸãã
Roivant Sciences Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îRoivant Sciences Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Dexcel Pharma Technologies, Ltd.
Fidelity Management & Research Company LLC
Ramaswamy (Vivek)
Dexcel Pharma Technologies, Ltd.
Fidelity Management & Research Company LLC
Ramaswamy (Vivek)
Roivant Sciences LtdïŒROIVïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãRoivant Sciences Ltdã®æ ªåŒãä¿æããŠããæ©é¢ã¯690瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ526.70Mã§ãå
šäœã®77.13%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-35.29%å¢å ããŠããŸãã
Roivant Sciences Ltdã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q1ã«ãããŠãVTAMAéšéãRoivant Sciences Ltdã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯55.13Mã§ãå
šåçã®--%ãå ããŠããŸãã
